---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-014118"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T12:38:14.725614+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech FY2022 net loss $40.9M; cash to Q3 2024; PDS0101 shows 100% response in cervical cancer

## Summary
- Net loss for 2022 was $40.9M ($1.43/share) vs $16.9M ($0.66/share) in 2021; R&D expenses rose to $29.4M.
- Cash balance of $73.8M as of Dec 31, 2022; management expects funds into Q3 2024.
- FDA meeting supported registrational pathway for triple combo (PDS0101, PDS0301, ICI) in HPV+ cancers.
- IMMUNOCERV trial: 100% clinical response (9/9 >60% tumor shrinkage) in high-risk cervical cancer patients.
- Signed exclusive global license for PDS0301 from Merck KGaA for $10M ($5M cash + $5M in stock).

## SEC filing metadata
- accession: 0001140361-23-014118
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036123014118/0001140361-23-014118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036123014118/brhc10050432_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-014118
- JSON: https://secwatch.observer/filing/0001140361-23-014118.json
- Plain text: https://secwatch.observer/filing/0001140361-23-014118.txt

## Key facts
- Earnings Releases
  PDS Biotechnology Corp reported the year ended December 31, 2022 results: net income approximately $40.9 million, EPS $1.43 per basic share and diluted share.
  - Period: the year ended December 31, 2022
  - Net income: approximately $40.9 million
  - EPS: $1.43 per basic share and diluted share
  - Result: reported results
  source text: Net loss for the year ended December 31, 2022 was approximately $40.9 million, or $1.43 per basic share and diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036123014118/0001140361-23-014118-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.